These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 33358430)

  • 21. What do research ethics committees say about applications to do cancer trials?
    Dixon-Woods M; Angell E; Tarrant C; Thomas A
    Lancet Oncol; 2008 Aug; 9(8):700-1. PubMed ID: 18672207
    [No Abstract]   [Full Text] [Related]  

  • 22. What are the expected developments in the medical treatment of bladder cancer.
    Bellmunt J
    Eur J Cancer; 2011 Sep; 47 Suppl 3():S294-7. PubMed ID: 21943989
    [No Abstract]   [Full Text] [Related]  

  • 23. Novel therapeutics in combination with radiotherapy to improve cancer treatment: rationale, mechanisms of action and clinical perspective.
    Verheij M; Vens C; van Triest B
    Drug Resist Updat; 2010; 13(1-2):29-43. PubMed ID: 20167530
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular characteristics therapy in AML.
    Radich GP
    Clin Adv Hematol Oncol; 2009 Jun; 7(6):11-4. PubMed ID: 19645131
    [No Abstract]   [Full Text] [Related]  

  • 25. SOP 09: Statistical design and analysis.
    Onkologie; 2003 Oct; 26 Suppl 6():43-7. PubMed ID: 23570186
    [No Abstract]   [Full Text] [Related]  

  • 26. Lipid-based nanoparticulate systems for the delivery of anti-cancer drug cocktails: Implications on pharmacokinetics and drug toxicities.
    Chiu GN; Wong MY; Ling LU; Shaikh IM; Tan KB; Chaudhury A; Tan BJ
    Curr Drug Metab; 2009 Oct; 10(8):861-74. PubMed ID: 20214582
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic potential of investigational CHK-1 inhibitors for the treatment of solid tumors.
    Babiker HM; McBride A; Cooke LS; Mahadevan D
    Expert Opin Investig Drugs; 2017 Sep; 26(9):1063-1072. PubMed ID: 28745064
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The pharmacogenomics of drug resistance to protein kinase inhibitors.
    Gillis NK; McLeod HL
    Drug Resist Updat; 2016 Sep; 28():28-42. PubMed ID: 27620953
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review.
    Alvarez Secord A; O'Malley DM; Sood AK; Westin SN; Liu JF
    Gynecol Oncol; 2021 Aug; 162(2):482-495. PubMed ID: 34090705
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Measurement of chemoresistance markers in patients with stage III non-small cell lung cancer: a novel approach for patient selection.
    Brooks KR; To K; Joshi MB; Conlon DH; Herndon JE; D'Amico TA; Harpole DH
    Ann Thorac Surg; 2003 Jul; 76(1):187-93; discussion 193. PubMed ID: 12842538
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A biological perspective on the selection of stage II colorectal cancer patients for adjuvant chemotherapy.
    Iacopetta B
    Ann Oncol; 2002 Sep; 13(9):1510. PubMed ID: 12196384
    [No Abstract]   [Full Text] [Related]  

  • 32. Resistance to metronomic chemotherapy and ways to overcome it.
    Riesco-Martinez M; Parra K; Saluja R; Francia G; Emmenegger U
    Cancer Lett; 2017 Aug; 400():311-318. PubMed ID: 28259819
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Angiogenesis and chemotherapy resistance: optimizing chemotherapy scheduling using mathematical modeling.
    Bodzioch M; Bajger P; Foryś U
    J Cancer Res Clin Oncol; 2021 Aug; 147(8):2281-2299. PubMed ID: 34050795
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Paclitaxel combination therapy in the treatment of metastatic breast cancer: a review.
    Holmes FA
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):46-56. PubMed ID: 8893900
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Can Immunogenic Chemotherapies Relieve Cancer Cell Resistance to Immune Checkpoint Inhibitors?
    Rivera Vargas T; Apetoh L
    Front Immunol; 2019; 10():1181. PubMed ID: 31191545
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of poly(ADP-ribose) polymerase inhibitors in the treatment of BRCA-mutated breast cancer.
    Sulai NH; Tan AR
    Clin Adv Hematol Oncol; 2018 Jul; 16(7):491-501. PubMed ID: 30067621
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Investigational PARP inhibitors for the treatment of biliary tract cancer: spotlight on preclinical and clinical studies.
    Mehta R; Wood AC; Yu J; Kim R
    Expert Opin Investig Drugs; 2021 Apr; 30(4):451-461. PubMed ID: 33660569
    [No Abstract]   [Full Text] [Related]  

  • 38. An audience with Tatiana Prowell. Interviewed by Asher Mullard.
    Prowell T
    Nat Rev Drug Discov; 2014 Jun; 13(6):410-1. PubMed ID: 24875091
    [No Abstract]   [Full Text] [Related]  

  • 39. An update of new targets for cancer treatment: receptor-mediated signals.
    Ciardiello F
    Ann Oncol; 2002; 13 Suppl 4():29-38. PubMed ID: 12401663
    [No Abstract]   [Full Text] [Related]  

  • 40. Capsaicinoids enhance chemosensitivity to chemotherapeutic drugs.
    Friedman JR; Richbart SD; Merritt JC; Perry HE; Brown KC; Akers AT; Nolan NA; Stevenson CD; Hurley JD; Miles SL; Tirona MT; Valentovic MA; Dasgupta P
    Adv Cancer Res; 2019; 144():263-298. PubMed ID: 31349900
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.